Table 3 MiR-26 delivery systems and concentrations

ADSCs

Transfected with miR-26-promoter

[36]

HpMSC-EVs

Unknown

WO2021225214

Self-complementary AAV (scAAV)

Unknown

[172]

AAV

40 nM

[173]

Aptamer chimera

33.5 pmol/g

[174]

EC-exos

100 nM

[175]

Engineered exos

0.12 pmol/μg

[176]

Enhancer delivery system, including HyStem-HP hydrogel, hBMMSCs, and Cy-3-labeled agomir (miRNA enhancer)

50 nM

[177]

293 T-exos

100 μg

[178]

PEI, PGEA, and HA-SS-PGEA

60 pmol

[179]

Lamp2b-exos

40 µg (exosomes)

[180]

Light_PEG chimera nanoparticles

0.9 mg/kg (Pharmacokinetics, BALB/c mice), 2.4 mg/kg (breast cancer models)

[181]

MSNs-PEI-KALA peptide system

0.1 nmol/μL

[182]

Anti-GPC3 scFv-modified exos

20 nM

[183]

PLLA NF scaffold attached to PLGA microspheres

60 pmol

[184]

PLGA nanocomplexes

20 ng/μL

[185]

PPHAuNCs-TNCs

2.2 mg/kg

[186]

PEI/QDs nanoparticle delivery vehicle

1 µg

[187]

SWCNT

40 mg/mL (SWCNT-miR-26a)

[188]

PEG hydrogels

0.06 pmol/μL

[189]

ScAAV8

Unknown

[190]

SMSCs-exos engineered with RVG peptide

100 µg/week (RVG-miR-26a-Exos)

[191]

RALA peptide

50 µg/mL

[192]

TEXs

1 nmol/μg exosomes

[193]